These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 21363862)

  • 1. How doctors are re-engineering the immune system to fight HIV infection.
    Roehr B
    BMJ; 2011 Mar; 342():d1373. PubMed ID: 21363862
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted gene editing enters clinic.
    Ledford H
    Nature; 2011 Mar; 471(7336):16. PubMed ID: 21368795
    [No Abstract]   [Full Text] [Related]  

  • 3. The emerging race to cure HIV infections.
    Cohen J
    Science; 2011 May; 332(6031):784-5, 787-9. PubMed ID: 21566173
    [No Abstract]   [Full Text] [Related]  

  • 4. Autologous CCR5-modified CD4 T-cells effective in HAART nonresponders.
    AIDS Patient Care STDS; 2011 Nov; 25(11):693. PubMed ID: 22132424
    [No Abstract]   [Full Text] [Related]  

  • 5. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection.
    de Roda Husman AM; Blaak H; Brouwer M; Schuitemaker H
    J Immunol; 1999 Oct; 163(8):4597-603. PubMed ID: 10510404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
    Swan CH; Bühler B; Steinberger P; Tschan MP; Barbas CF; Torbett BE
    Gene Ther; 2006 Oct; 13(20):1480-92. PubMed ID: 16738691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Building an HIV-proof immune system.
    Cohen J
    Science; 2007 Aug; 317(5838):612-4. PubMed ID: 17673648
    [No Abstract]   [Full Text] [Related]  

  • 8. Positive results with autologous transplant of ZFN-modified CD4 T-cells: a step toward a practical, functional cure for HIV.
    AIDS Patient Care STDS; 2011 Nov; 25(11):693. PubMed ID: 22023317
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunological effects of antiretroviral and immune therapies for HIV.
    Kelleher AD; Al-Harthi L; Landay AL
    AIDS; 1997; 11 Suppl A():S149-55. PubMed ID: 9451979
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immune-based therapies and HIV infection].
    Weiss L
    Ann Med Interne (Paris); 2002 Jun; 153(4):227-36. PubMed ID: 12218888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression.
    Butticaz C; Ciuffi A; Muñoz M; Thomas J; Bridge A; Pebernard S; Iggo R; Meylan P; Telenti A
    Antivir Ther; 2003 Oct; 8(5):373-7. PubMed ID: 14640383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Personalized therapy for HIV infection].
    Winckler T
    Pharm Unserer Zeit; 2011 May; 40(3):188-9. PubMed ID: 21698605
    [No Abstract]   [Full Text] [Related]  

  • 13. Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands.
    Guan Y; Abdelwahab S; Kamin-Lewis R; DeVico AL; Lewis GK
    PLoS One; 2008; 3(10):e3481. PubMed ID: 18941536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 immunogen (remune).
    Newsline People AIDS Coalit N Y; 1998 Dec; ():36. PubMed ID: 11367099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection.
    Soares R; Foxall R; Albuquerque A; Cortesão C; Garcia M; Victorino RM; Sousa AE
    J Virol; 2006 Dec; 80(24):12425-9. PubMed ID: 17035326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
    Cohen OJ; Vaccarezza M; Lam GK; Baird BF; Wildt K; Murphy PM; Zimmerman PA; Nutman TB; Fox CH; Hoover S; Adelsberger J; Baseler M; Arthos J; Davey RT; Dewar RL; Metcalf J; Schwartzentruber DJ; Orenstein JM; Buchbinder S; Saah AJ; Detels R; Phair J; Rinaldo C; Margolick JB; Pantaleo G; Fauci AS
    J Clin Invest; 1997 Sep; 100(6):1581-9. PubMed ID: 9294127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients benefit from using own CD4 T-cells.
    AIDS Alert; 2002 Apr; 17(4):48-9. PubMed ID: 12030201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering cellular resistance to HIV.
    Kay MA; Walker BD
    N Engl J Med; 2014 Mar; 370(10):968-9. PubMed ID: 24597871
    [No Abstract]   [Full Text] [Related]  

  • 19. Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy.
    Kourtis AP; Ibegbu CC; Theiler R; Xu YX; Bansil P; Jamieson DJ; Lindsay M; Butera S; Duerr A
    J Infect Dis; 2007 Apr; 195(7):965-72. PubMed ID: 17330786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signalling.
    Lin YL; Mettling C; Portalès P; Réant B; Robert-Hebmann V; Reynes J; Clot J; Corbeau P
    AIDS; 2006 Jun; 20(10):1369-77. PubMed ID: 16791011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.